8-K: Creative Medical Technology Holds 2025 Annual Meeting

Creative Medical Technology Holdings, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, executive compensation was approved, and Haynie & Company was ratified as independent accountants.

Summary

• The 2025 Annual Meeting of Stockholders was held on December 18, 2025.
• A quorum was met with 1,589,800 shares of common stock, representing 61.5% of outstanding shares, present or represented by proxy.
• All five director nominees—Timothy Warbington, Donald Dickerson, Michael H. Finger, Susan Snow, and Bruce S. Urdang, Esq.—were elected to the Board.
• The compensation of the company's named executive officers was approved by stockholders.
• The appointment of Haynie & Company as the company's independent registered public accountants was ratified.

Sentiment

Score: 7

Explanation: The filing reports the successful passage of all management-backed proposals at the annual meeting, indicating stable corporate governance and shareholder support, despite some dissenting votes and broker non-votes.

Positives

• All five director nominees were successfully elected to the Board, ensuring continuity in leadership.
• Stockholders approved the compensation of named executive officers, indicating support for current executive remuneration practices.
• The appointment of Haynie & Company as independent registered public accountants was ratified, maintaining stability in financial oversight.
• A quorum of 61.5% of outstanding shares was achieved, demonstrating sufficient shareholder engagement for the meeting.

Negatives

• A notable number of broker non-votes (1,113,524) were recorded for the executive compensation proposal, indicating a significant portion of beneficial owners did not provide voting instructions.
• While all proposals passed, there were votes withheld for director nominees and votes against executive compensation and auditor ratification, suggesting some level of shareholder dissent.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmed the composition of the Board of Directors, approved executive compensation, and ratified the independent auditor, providing clarity on corporate governance.
• Management: Received shareholder endorsement for the current board and executive compensation, reinforcing their mandate.
• Auditors: Haynie & Company's appointment was ratified, confirming their role for the upcoming fiscal period.

Key Dates

Recommendation

The filing details the routine outcomes of an annual stockholder meeting, including the re-election of directors, approval of executive compensation, and ratification of auditors. No new material financial or operational information was disclosed that would alter the company's fundamental valuation or investment outlook. Therefore, a 'hold' recommendation is appropriate as there's no immediate catalyst for a change in investment position based solely on this filing.

Keywords

Creative Medical Technology Holdings, CELZ, Annual Meeting, Stockholders, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance